Abstract: Systems and method are disclosed herein that relate to support for virtual Time-Sensitive Networking (TSN) bridge management, Quality of Service (QoS) mapping, and TSN related scheduling in a cellular communications system. In some embodiments, a method performed by one or more network nodes of a cellular communications system operating as a virtual TSN bridge of a TSN network comprises providing, to a controller associated with the TSN network, parameters that relate to capabilities of the virtual TSN bridge. The parameters that relate to the capabilities of the virtual TSN bridge comprise a first parameter that defines a clock accuracy of an entity in the cellular communications system that operates gating control for the virtual TSN bridge and a second parameter that informs the controller associated with the TSN network that the virtual TSN bridge or a particular egress port of the virtual TSN bridge is restricted to exclusive gating.

Abstract: Provided are improved storage-stable liquid pharmaceutical antibody formulations. In particular, liquid aqueous pharmaceutical formulations of Adalimumab based on alternative buffer systems to citrate/phosphate and pharmaceutical containers like auto-injection devices containing the same are described.

Abstract: The invention relates to nanocomposites comprising of (i) hydrogels synthetized by copolymerization of N-isopropylacrylamide and/or acrylamide and/or acrylic acid monomers and of (ii) layer silicates, and to the process for preparing them. The invention covers osmotically active hydrogel expanders containing said nano-composites, suitable for tissue expansion and the use of said materials for obtaining live skin.

Abstract: uPAR-targeting cyclic peptide compounds have 11 amino acids that correspond to human uPA(20-30) [SEQ ID NO:2], or are substitution variants at selected positions. The N and C terminal residues of these peptides are joined by a linking group L, so that the linear dimension between the &agr;-carbons of the first and the eleventh amino acids is between about 4 and 12 Angstrom units. These cyclic peptides may be further conjugated to diagnostic labels or therapeutic moieties such as radionuclides. Such compounds are useful for targeting uPAR expressed in pathological tissues and for inhibiting the binding of uPA to the uPAR. The pharmaceutical and therapeutic compositions inhibit cell migration, cell invasion, cell proliferation or angiogenesis, or induce apoptosis, and are thus useful for treating diseases or condition associated with undesired cell migration, invasion, proliferation, or angiogenesis, most notably cancer. The cyclic peptides are also used to detect and isolate cells expressing uPAR.

Abstract: Cyclic peptide compounds having 11 amino acids joined by a linking unit L, such that the linear dimension between the C&agr; carbon of the first amino acid and the C&agr; carbon of eleventh amino acid is between about 4 and 12 Ångstrom units; are useful for inhibiting the binding of uPA to the uPAR receptor.: Methods for using the cyclic peptide compounds, and compositions containing them, for inhibiting the growth or metastasis of cancerous tumors are also disclosed.

Abstract: Cyclic peptide compounds having 11 amino acids joined by a linking unit L, such that the linear dimension between the C&agr; carbon of the first amino acid and the C&agr; carbon of eleventh amino acid is between about 4 and 12 Ångstrom units; are useful for inhibiting the binding of uPA to the uPAR receptor. Methods for using the cyclic peptide compounds, and compositions containing them, for inhibiting the growth or metastasis of cancerous tumors are also disclosed.

Abstract: Cyclic peptide compounds having 11 amino acids joined by a linking unit L, such that the linear dimension between the C.sup..alpha. carbon of the first amino acid and the C.sup..alpha. carbon of eleventh amino acid is between about 4 and 12 .ANG.ngstrom units; are useful for inhibiting the binding of uPA to the uPAR receptor. Methods for using the cyclic peptide compounds, and compositions containing them, for inhibiting the growth or metastasis of cancerous tumors are also disclosed.

Abstract: The invention relates to synergistically active veterinary compositions useful particularly for the treatment of mastitis and metritis. The invention further relates to a process for preparing these compositions. The compositions according to the invention comprise, based on 1 part by weight of 6,9,18-tris(2-aminoethyl) -15-benzyl-21-[.sup.- 2,8-bis(2-aminoethyl)-5-(1-hydroxyethyl) -15-methyl-4,7,10-trioxo-3,6,9-triazaheptadecanamido]-3-(1-hydroxyethyl)-1 2-isobutyl-1,4,7,10,13,16,19-heptaazacyclotricosane-2, 5,8,11,14,17,20-heptaone or a pharmaceutically acceptable acid addition salt thereof, 1 to 1000 parts by weight of 1-(2-chlorophenyl)-diphenylmethyl-1H-imidazole or 1 to 400 parts by weight of 2-methyl-5,7-dichloro-8-hydroxyquinoline, respectively, optionally in admixture with carriers and/or additives commonly used in the pharmaceutical industry.

Abstract: The invention relates to a synergistic veterinary composition and/or a fodder premix useful for preventing or curing bacterial, fungal and protozoic infection particularly occurring at poultry species. Furthermore the invention relates to a process for preparing same. The composition or premix contains 1 to 100 parts by mass of 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine and/or 1 to 100 parts by mass of 2,4-diamino-5-(3,4-dimethoxybenzyl)pyrimidine as well as 1 to 100 parts by mass of 2,6-dimethoxy-4-sulfanilamidopyrimidine or a pharmaceutically acceptable salt thereof and 1 to 100 parts by mass of 8-hydroxyquinoline or a pharmaceutically acceptable acid addition salt thereof optionally in admixture with carrier(s) and/or additive(s) commonly used in the pharmaceutical industry or for the preparation of premixes.

Abstract: The invention relates to a synergistic antibiotic composition useful for the treatment of respiratory, gastrointestinal or urinary infections and septicaemia of domestic animals. The composition comprises tiamulin hydrogen fumarate and an aminoglycoside antibiotic or a pharmaceutically acceptable salt thereof in a weight ratio of 5:1 to 1:5. The active components are admixed or diluted with a carrier, used in veterinary therapy, in a weight ratio of 1:1 to 1:50 and formulated for oral or parenteral application.

Abstract: An apparatus and a method for at least partially drying a first substantially granular material inclusive of a fluid, and mixing the first material with a second substantially granular material, includes a container, a conveyor disposed in the container, and an air supply for blowing air into the mixed first and second materials. The materials then become at least partially loosened, are dried by the air blown thereinto, are moved operatively at least partially upwards by the conveyor, and are then allowed to drop downwards within the container.

Abstract: There is disclosed a process for preparing fertilizers containing dicalcium phosphate from phosphates of mineral origin by mechanical activation. According to the invention grains larger than 5 mm of the sized or unsized starting phosphate compound of mineral origin are granulated up to a grain size of 1 to 4 mm, the granulated phosphate obtained is admixed with monocalcium phosphate and the phosphate crystals are activated by colliding the grains of the mixture at a speed of 70 to 120 m/sec.The fertilizer prepared according to the invention possesses numerous advantages over the known phosphate fertilizers from technological and applicational point of view as well.